Akili Interactive Labs on Monday reported that its late-stage study of a video game designed to treat kids with ADHD met its primary goal, a big step in the Boston company’s quest to get approval for what it hopes will be the first prescription video game.
In a study of 348 children between the ages of 8 and 12 diagnosed with ADHD, those who played Akili’s action-packed game on a tablet over four weeks saw statistically significant improvements on metrics of attention and inhibitory control, compared to children who were given a different action-driven video game designed as a placebo. The company plans next year to file for approval with the Food and Drug Administration.
“We are directly targeting the key neurological pathways that control attention and impulsivity,” said Akili CEO Eddie Martucci. The study “was meant to be a strong objective test to ask: Is it the targeting we do in the brain or is it general engagement with a treatment that’s exciting and interesting … that actually leads to these targeted effects? And so I think we clearly see that it’s the targeted algorithms that we have.”
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect